thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 9, 2026

FDA approves Bayer stroke drug, rejects Novocure cancer application

The agency added a possible eye-risk warning to GLP-1 labels and cleared an injected antibody treatment for recurrent head and neck cancer.

  • Updated
  • Read from 13 articles, 11 publications
  • A +5

Today in brief

Bayer’s Sunharbo became the first Factor XIa inhibitor approved to reduce stroke risk, while the FDA rejected Novocure’s metastatic cancer application.123 The FDA also ordered an eye-condition warning on GLP-1 labels and authorized an antibody treatment given under the skin for recurrent head and neck cancer.456

FDA approves Bayer’s Sunharbo to prevent recurrent stroke

The FDA approved Sunharbo with antiplatelet therapy for adults at risk of another stroke after a recent mild-to-moderate ischemic stroke or a high-risk transient ischemic attack.1 It is the first Factor XIa inhibitor approved for this use.1

In the Phase 3 OCEANIC-STROKE trial, Sunharbo reduced ischemic stroke risk by 26% compared with placebo, with both groups also receiving antiplatelet therapy.1 Another stroke occurred in 6.2% of Sunharbo recipients and 8.4% of placebo recipients.7

Major bleeding rates were similar overall, but higher with Sunharbo among patients older than 75 and during the first 90 days of treatment.1 Gastrointestinal bleeding was also more common, and diarrhea was the most frequently reported adverse reaction.1 The FDA advises against combining Sunharbo with certain drugs, including carbamazepine, or using it in patients with moderate or severe liver impairment.1 Sunharbo isn’t approved to prevent stroke in people with atrial fibrillation. The FDA advises pausing it before elective procedures and after thrombolysis for acute ischemic stroke.1

FDA adds potential vision risk to GLP-1 labels

The FDA is requiring class-wide label changes warning that GLP-1 medicines may be associated with non-arteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause sudden vision loss.45 Labels will tell patients to report sudden vision changes and recommend referral to an eye specialist when NAION is suspected.5 Clinicians may consider stopping treatment if NAION occurs, unless the benefits clearly outweigh the risks. The warning is not boxed.5

Evidence on the risk is mixed. An FDA analysis found no statistically significant increase versus SGLT-2 inhibitors, but a 43% higher risk versus DPP-4 inhibitors.5 A pooled analysis of 126 trials found 15 probable cases, 10 among GLP-1 users, with rates of 6.4 versus 3.8 cases per 100,000 person-years in comparison patients.5 Other studies reached different results. A U.S. health-record analysis found 76% higher risk among semaglutide or tirzepatide users, while a Cleveland Clinic analysis found no statistically significant increase.5

The FDA said animal data showed no mechanism linking the medicines to NAION and that adverse-event reports were difficult to interpret because risk factors are common among users.5 Novo Nordisk said the evidence does not establish cause and effect. The FDA said observational research consistently found higher risk among new GLP-1 users with type 2 diabetes than among patients starting comparator drugs.5

FDA rejects Novocure’s metastatic cancer treatment

The FDA denied Novocure approval for its metastatic cancer treatment.3 Novocure said the agency was uncertain about the degree of clinical benefit for brain metastases.3

Also worth knowing

  • S

    The U.S. imposed new rules for ordering synthetic DNA to deter bioterrorism. Biosecurity experts gave the policy tempered praise.8

  • The MHRA awarded Innovation Passports to three investigational medicines for Huntington’s disease, non-small cell lung cancer and early Alzheimer’s disease. They remain in development, and any future availability depends on evidence of safety, effectiveness and value.9

  • China authorized Bio-Thera’s BAT2506, sold as Ashuli, for ankylosing spondylitis and rheumatoid arthritis. It is the country’s first approved biosimilar to Simponi.10

  • A Vital Transformation analysis linked the Inflation Reduction Act’s introduction with a 37% drop in follow-on small-molecule oncology studies, a 27% decline in lead-indication approvals and a 14% decrease in the share of oncology studies focused on orphan indications.11

  • The FDA invited public comment on a discussion paper about medical robots with autonomous or remote-operation functions as it develops policy for the devices.12

  • Treasury proposed COINS Act regulations that could make it harder for U.S.-backed companies to pursue Chinese biotech assets while potentially giving European drugmakers more room to do so.13

Also published